126 related articles for article (PubMed ID: 16007002)
1. Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets.
Kirchheiner J; Henckel HB; Franke L; Meineke I; Tzvetkov M; Uebelhack R; Roots I; Brockmöller J
Pharmacogenet Genomics; 2005 Aug; 15(8):579-87. PubMed ID: 16007002
[TBL] [Abstract][Full Text] [Related]
2. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Roots I; Brockmöller J
Pharmacogenetics; 2002 Oct; 12(7):571-80. PubMed ID: 12360109
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
4. Doxepin inhibits CYP2D6 activity in vivo.
Szewczuk-Bogusławska M; Kiejna A; Beszłej JA; Orzechowska-Juzwenko K; Milejski P
Pol J Pharmacol; 2004; 56(4):491-4. PubMed ID: 15520506
[TBL] [Abstract][Full Text] [Related]
5. A fatal doxepin poisoning associated with a defective CYP2D6 genotype.
Koski A; Ojanperä I; Sistonen J; Vuori E; Sajantila A
Am J Forensic Med Pathol; 2007 Sep; 28(3):259-61. PubMed ID: 17721180
[TBL] [Abstract][Full Text] [Related]
6. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
[TBL] [Abstract][Full Text] [Related]
7. Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin.
Haritos VS; Ghabrial H; Ahokas JT; Ching MS
Pharmacogenetics; 2000 Oct; 10(7):591-603. PubMed ID: 11037801
[TBL] [Abstract][Full Text] [Related]
8. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.
Kirchheiner J; Keulen JT; Bauer S; Roots I; Brockmöller J
J Clin Psychopharmacol; 2008 Feb; 28(1):78-83. PubMed ID: 18204346
[TBL] [Abstract][Full Text] [Related]
9. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.
Gan SH; Ismail R; Wan Adnan WA; Zulmi W
Mol Diagn Ther; 2007; 11(3):171-81. PubMed ID: 17570739
[TBL] [Abstract][Full Text] [Related]
10. Stereoselective pharmacokinetics of doxepin isomers.
Midha KK; Hubbard JW; McKay G; Hawes EM; Korchinski ED; Gurnsey T; Cooper JK; Schwede R
Eur J Clin Pharmacol; 1992; 42(5):539-44. PubMed ID: 1607001
[TBL] [Abstract][Full Text] [Related]
11. Biotransformation of doxepin by Cunninghamella elegans.
Moody JD; Freeman JP; Cerniglia CE
Drug Metab Dispos; 1999 Oct; 27(10):1157-64. PubMed ID: 10497142
[TBL] [Abstract][Full Text] [Related]
12. Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity.
Kirchheiner J; Sasse J; Meineke I; Roots I; Brockmöller J
Pharmacogenetics; 2003 Dec; 13(12):721-8. PubMed ID: 14646691
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
[TBL] [Abstract][Full Text] [Related]
14. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy.
Ververs FF; Voorbij HA; Zwarts P; Belitser SV; Egberts TC; Visser GH; Schobben AF
Clin Pharmacokinet; 2009; 48(10):677-83. PubMed ID: 19743889
[TBL] [Abstract][Full Text] [Related]
15. Fatal doxepin intoxication--suicide or slow gradual intoxication?
Neukamm MA; Vogt S; Hermanns-Clausen M; Naue J; Thierauf A; Auwärter V
Forensic Sci Int; 2013 Apr; 227(1-3):82-4. PubMed ID: 22999230
[TBL] [Abstract][Full Text] [Related]
16. A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.
Johansson H; Gandini S; Serrano D; Gjerde J; Lattanzi M; Macis D; Guerrieri-Gonzaga A; Aristarco V; Mellgren G; Lien E; DeCensi A; Bonanni B
Breast Cancer Res Treat; 2016 Aug; 159(1):97-108. PubMed ID: 27484880
[TBL] [Abstract][Full Text] [Related]
17. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics.
Furman KD; Grimm DR; Mueller T; Holley-Shanks RR; Bertz RJ; Williams LA; Spear BB; Katz DA
Pharmacogenetics; 2004 May; 14(5):279-84. PubMed ID: 15115913
[TBL] [Abstract][Full Text] [Related]
18. CYP2D6 genotype dependent oxycodone metabolism in postoperative patients.
Stamer UM; Zhang L; Book M; Lehmann LE; Stuber F; Musshoff F
PLoS One; 2013; 8(3):e60239. PubMed ID: 23555934
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
20. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.
Lisbeth P; Vincent H; Kristof M; Bernard S; Manuel M; Hugo N
Eur J Clin Pharmacol; 2016 Feb; 72(2):175-84. PubMed ID: 26514968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]